Arnold Professional Pharmacy, Arnold, MD

Is Arnold Professional Pharmacy registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Arnold Professional Pharmacy hold a Maryland pharmacy license?

State pharmacy license records for Maryland are not checked: the board’s license verification is an interactive search, which this index does not use. This index reads only that state’s board actions.

Has Arnold Professional Pharmacy had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Dec 27, 2022), 1 untitled letter (Dec 12, 2019), 1 state referral letter (Dec 27, 2022) and 1 FMD-145 letter (Dec 27, 2022) for Arnold Professional Pharmacy. State board actions: no Maryland Board of Pharmacy action under this exact name and city was found in the Maryland Board of Pharmacy’s posted orders against permit holders that this index could read (actions dated Jan 2, 2007 to Oct 20, 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Arnold Professional Pharmacy
Location
Arnold, MD
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Dec 27, 2022
FDA Data Dashboard inspections
2 inspections: 2 VAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 8 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Arnold Professional Pharmacy, a 503A facility, with 5 dated actions.

Document
Dec 27, 2022Warning letter close-outWarning Letter Closeout Issued 12/27/2022Not linked by FDA
Dec 27, 2022State referral letterState Referral Letter Issued 12/27/2022Not linked by FDA
Dec 27, 2022FMD-145 letterFMD-145 Letter Issued 12/27/2022Not linked by FDA
Mar 18, 2022Form 483483 Issued 03/18/2022FDA copy (archived)
Dec 12, 2019Untitled letterUntitled Letter Issued 12/12/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Arnold Professional Pharmacy, Arnold, MD (FEI number 3012283530), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 18, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30122835301165132
Sep 5, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30122835301064498

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 8 numbered observations in all, across 3 inspections ending May 6, 2016 to Mar 18, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 7, 2022 to Mar 18, 2022: 3 observations

Firm on the cover
Arnold Professional Pharmacy, 1460 Ritchie Hwy Ste 103, Arnold, MD 21012 -2704
FEI number
3012283530
Establishment type on the cover
Producer of non-sterile drug products
FDA district office on the cover
11155 Dolfield Boulevard, Suite 117 Owings Mills, MD 21117
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced beta-lactam drugs without providing adequate segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically, amoxicillin, ceftazidime, and cefuroxime were produced in the "general compounding room" where non-beta-lactam containing products are also produced. There are no dedicated spaces, decontamination steps or controls in place to prevent cross-contamination following production of beta-lactam products in the "general compounding room". For example, on March 2, 2022, "MILES SOLUTION" (Rx <Redacted B4>), which contains amoxicillin, was produced using a non-dedicated graduated cylinder. Similarly, on Januaiy 10, 2022, "AMOXICILLIN 1 00MG/ML SUSP ANHYD" ( Rx <Redacted B4>) and on January 26, 2022, "AMOXICILLIN 50MG CAPSULES" (Rx <Redacted B4>) were produced using a non-dedicated <Redacted B4> Non-beta-lactam products were subsequently produced and released for distribution using the same non-dedicated equipment.

Observation 2

Non-microbial contamination was observed in your production area.

Specifically,

A. Two areas of black-brown discoloration of unknown source were observed on a ceiling tile in the "general compounding room" on March 9, 2022. The first area measured approximately six inches by one-fourth inch, and the second area measured approximately four inches by one-half inch. The ceiling tile was above a shelf containing closed containers of active pharmaceutical ingredients and other ingredients. The containers are not cleaned off prior to being placed in the hood for use in production operations.

• On March 7, 2022, your Phaimacy Technician, <Redacted B4> used a liquid hand soap to clean spatulas, capsule machine parts, and <Redacted B4> used in production operations.

b

• On March 8, 2022, <Redacted B4> used a household liquid detergent, <Redacted B4>, to clean similar equipment and utensils routinely used in the production of non-hazardous non-sterile drug products. Reusable glassware and utensils were utilized in, but not limited to, the production of the following: ...

Read the full 483 (PDF on fda.gov)

Observation 3

You use equipment in production of drug products that have difficult to clean surfaces.

Specifically, chipped/broken spatulas were observed on March 7 and 8, 2022, in the drying rack in the "general compounding room", creating a difficult to clean surface and a possible source for contamination. Spatulas are non-dedicated utensils that are used in production of various drug products such as creams and ointments.

Inspection Aug 21, 2018 to Sep 5, 2018: 1 observation

Firm on the cover
Arnold Professional Pharmacy, 1460 Ritchie Hwy Ste 103, Arnold, MD 21012-2704
FEI number
3012283530
Establishment type on the cover
Producer o f non- sterile drug p r oducts
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, your firm used <Redacted B4> used <Redacted B4> water in the production of a released and distributed drug product. <Redacted B4> water was used in the production of <Redacted B4> , Amlodipine lmg/mL, for a pediatric population.

Inspection May 2, 2016 to May 6, 2016: 4 observations

Firm on the cover
, 1460 Ritchie Highway, Suite 103 Arnold Professional Pharmacy, Arnold, .MD 21012
FEI number
3012283530
Establishment type on the cover
Producer of Non-Sterile Drugs
FDA district office on the cover
6000 Metro Drive, Suite 101 Baltimore,.MD 21215
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Testing and release of drug products for distribution do not include appropriate laboratory determination of satisfactory conformance to formal specifications and identity and strength of each active ingredient prior to release.

Specifically, the firm does not test batches of produced non-sterile drugs to ensure consistency and potency before products are released. The firm compounds REDACTED B4 drugs/day.

Observation 2

Records of the calibration checks of automatic, mechanical or electronic equipment, including computers or related systems are not maintained.

Specifically, the firm does not have any documentation demonstrating the calibration and service for the REDACTED B4 balance, REDACTED B4 machines REDACTED B4 thermometer and REDACTED B4. Further, there is no record of calibration of thermometers for the refrigerator, where compounded Lansoprazole 15 mg/5 ml for pediatric populations is stored.

Observation 3

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component or establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at

appropriate intervals.

Specifically, the firm relies solely on the Certificate of Analysis provided with each raw ingredient as no additional tests are conducted upon receipt.

Observation 4

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

Specifically, the firm does not consistently perform in-process checks on produced non-sterile drugs to reduce variability. The in-process checks is based on the REDACTED B4.

State board of pharmacy records

State pharmacy license records for Maryland are not checked: the board’s license verification is an interactive search, which this index does not use. This index reads only that state’s board actions. Board actions source.

What this covers: Orders and notices the Maryland Board of Pharmacy links on its Formal Disciplinary Actions page, read from each PDF: 2,109 documents listed, of which 1,337 are labeled with a person’s surname and initials (orders against pharmacists and technicians) and were not read; of the other 772, 328 had readable text, 438 scanned without a text layer and 6 that could not be downloaded. 312 name a permit holder rather than a pharmacist or technician; for 98 of them no city could be read from the document, so they cannot be matched to a page. Each is dated by the date on the board’s list, and the title and passage are copied from the PDF’s text layer, which for scanned orders is a machine reading of the page and can misread a letter, so open the document before relying on a quoted word. Maryland pharmacy permits themselves are not checked. 16 documents have no readable title. Actions in the data are dated Jan 2, 2007 to Oct 20, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.